- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01852942
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will:
- reverse existing lymphoid tissue fibrosis,
- restore lymphoid tissue architecture,
- increase the number and improve the function of peripheral and lymphatic CD4 T cells,
- decrease levels of systemic immune activation (IA),
- decrease size of the HIV reservoir, and
- be safe and well tolerated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled trial of 50 HIV-1 infected individuals on stable ART randomized in a 1:1 ratio to losartan (50 mg orally daily titrated to 100 mg daily) vs placebo for 30 months. We plan to enroll a total of 63 HIV infected subjects to ensure that 50 complete the protocol. All HIV infected subjects will undergo biopsies of inguinal lymph node (LN) and gut associated lymphatic tissue (GALT) for primary endpoint analysis at baseline, 12 and 30 months after study enrollment. Blood will be collected at least quarterly throughout the study and an intensive blood pharmacokinetic (PK) study will be conducted at month 1. All HIV infected subjects will be vaccinated with the quadrivalent human papillomavirus (HPV) vaccine at months 23, 25 and 29.5 to measure immune function. 5 HIV uninfected control subjects will also be enrolled.
The primary endpoint is to determine the impact of losartan on lymphoid tissue fibrosis in HIV infected, ART treated adults. This will be determined by measuring the amount of collagen deposition in lymphoid tissues and the integrity of the FRCn using immunohistochemistry (IHC) and quantitative image analysis (QIA).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, Division of Infectious Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
HIV infected participants:
Inclusion Criteria:
Participants must meet all of the following inclusion criteria to participate in this study:
HIV-1 infected.
-≥ 18 years of age.
Baseline peripheral CD4+ T cell count 200-600 cells/mm3 for at least two measures over the 6 months prior to study enrollment.
-≥ 12 months of stable ART, defined as use of a given drug regimen without disruption lasting ≥ 1 week in the period leading up to study enrollment.
- HIV viral load (VL) < 50 copies/mL for at least two consecutive measures over the 6 months prior to study enrollment.
- No contraindication to proposed study procedures.
- Women of child-bearing potential must be willing to use a form of effective contraception for the duration of the study. Effective contraception includes hormonal injection, implant or oral medication, IUD, diaphragm, or cervical cap with spermicide. Condoms cannot be used as the sole form of contraception.
Exclusion Criteria: Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
- Use of any immunomodulator within the 12 months prior to study enrollment. An immunomodulator for the purposes of this study is defined as a drug known to either diminish or augment a patient's immune system. Examples of these include, but are not limited to, systemic corticosteroids (use of topical steroids will be permitted), TNF-inhibitors, rituximab, cyclophosphamide, abatacept,cyclosporine, azathioprine, 6-mercaptopurine, methotrexate, sulfasalazine, cyclosporine, tacrolimus,sirolimus, and intravenous immune globulin.
- Current use of an ARB or ACEi.
- Current use of rifaximin, fluconazole or lithium given potential for drug interactions with losartan.
- Prior reaction or intolerance to an ARB or ACEi.
- Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence as diagnosed by a primary care physician or specialist. Examples of these include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease, psoriasis, polymyositis, dermatomyositis, vasculitis, sarcoidosis, Wegener's granulomatosis, giant cell arteritis, polyarteritis nodosa, gastrointestinal pemphigoid, eosinophilic colitis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, and hepatitis C.
- Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
- Baseline blood pressure < 110/70.
- Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 within 4 weeks of study initiation or history of advanced renal disease.
- AST and/or ALT > 3 times the upper limit of normal within 4 weeks of study enrollment.
- Potassium > 5.0 within 4 weeks of study enrollment.
- Pregnancy.
- In women of childbearing age, unwillingness to use birth control for the duration of the study.
- Breast feeding.
- Prior vaccination with an HPV vaccine, including Cervarix (GlaxoSmithKline) or Gardasil (Merck).
- History of hypersensitivity or severe allergic reactions to yeast.
HIV-uninfected:
Inclusion Criteria
Participants must meet all of the following inclusion criteria to participate in this study:
HIV uninfected.
-≥ 18 years of age.
- No contraindication to proposed study procedures.
Exclusion Criteria: Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
- Use of any immunomodulator within the 12 months prior to study enrollment (as defined above).
- Current use of an ARB or ACEi.
- Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence (as defined above).
- Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
- Pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar Pill
|
one tablet by mouth daily
|
Experimental: Losartan
|
Participants will start with 50 mg of losartan by mouth daily.
The dose will be increased to 100 mg by mouth daily after 14 days.
The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collagen Deposition in LT
Time Frame: 30 months
|
The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the amount of collagen deposition in LT using immunohistochemistry (IHC) and quantitative image analysis (QIA).
LT will be obtained at baseline, month 12 and month 30.
|
30 months
|
Integrity of the Fibroblastic Reticular Cell Network (FRCn)
Time Frame: 30 months
|
The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the Integrity of the fibroblastic reticular cell network (FRCn) using immunohistochemistry (IHC) and quantitative image analysis (QIA).
LT will be obtained at baseline, month 12 and month 30.
|
30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of CD4+ T Cells
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of CD4+ T cells in LT using IHC.
|
30 months
|
Frequency TUNEL+CD3+CD8+ T Cells
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of TUNEL+CD3+CD8+ T cells in LT using IHC.
|
30 months
|
Frequency of Cells Expressing TGF-beta and Lymphotoxin-beta
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of cells expressing TGF-beta and lymphotoxin-beta in LT using IHC.
|
30 months
|
Serum Concentration of IL-7
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by serum concentrations of IL-7 measured with ELISA.
|
30 months
|
Serum Concentration of TGF-beta
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by serum concentrations of TGF-beta measured with ELISA.
|
30 months
|
Immune Response to HPV Vaccination
Time Frame: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by measuring the immune response to HPV vaccination using flow cytometry to identify cells stimulated by specific HPV peptides.
|
30 months
|
Frequency of Activated T-cell Populations - Immunofluorescent Staining
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the frequency of activated T-cell populations (specifically CD3+CD4+CD38+, CD3+,CD8+CD38+,CD4+Ki67+ and CD8+Ki67+ T cells) in LT using immunofluorescence staining
|
30 months
|
Percent of Activated T Cells in PBMCs - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated Macrophages in PBMCs - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated Dendritic Cells in PBMCs - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated T Cells in LT - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Percent of Activated Macrophages in LT - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Percent of Activated Dendritic Cells in LT - Flow Cytometry
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Intracellular Concentration of IL-17 in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IFNg in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-2 in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of TNF in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-10 in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of GM-CSF in PBMCs
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-17 in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IFNg in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-2 in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of TNF in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-10 in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of GM-CSF in LT
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Plasma Concentration of LPS
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of LPS by ELISA.
|
30 months
|
Plasma Concentration of sCD14
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of sCD14 by limulus assay.
|
30 months
|
Plasma Concentration of I-FABP
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of I-FABP using ELISA.
|
30 months
|
Plasma Concentration of IL-1b
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1b using ELISA.
|
30 months
|
Plasma Concentration of IL-1RA
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1RA using ELISA.
|
30 months
|
Plasma Concentration of IL-6
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-6 using ELISA.
|
30 months
|
Plasma Concentration of TNF
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of TNF using ELISA.
|
30 months
|
Plasma Concentration of Amyloid A
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of amyloid A using ELISA.
|
30 months
|
Plasma Concentration of CRP
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of CRP using ELISA.
|
30 months
|
Plasma Concentration of D-dimer
Time Frame: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of D-dimer using ELISA.
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in LN - Radiolabeled ISH
Time Frame: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using radiolabeled in situ hybridization (ISH).
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in LN - RNAscopeTM in Situ Technology
Time Frame: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using RNAscopeTM in situ technology.
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in GALT - Radiolabeled in Situ Hybridization (ISH)
Time Frame: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT radiolabeled in situ hybridization (ISH).
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in GALT - RNAscopeTM in Situ Technology
Time Frame: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT using RNAscopeTM in situ technology.
|
30 months
|
Concentration of Losartan and Antiretrovirals (ARVs)
Time Frame: 30 months
|
Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring levels of ARVs and losartan in plasma and peripheral blood mononuclear cells (PBMCs).
|
30 months
|
Intracellular Concentration of Losartan and Antiretrovirals (ARVs)
Time Frame: 30 months
|
Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring intracellular concentration of losartan and ARVs in lympoidtissue.
|
30 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Dendritic Cell and CD4 T Cell Interactions With the FRCn
Time Frame: 30 months
|
As an exploratory endpoint, we will determine the impact of losartan on frequency of dendritic cell and CD4 T cell interactions with the FRCn.
This will be determined using two-photon microscopy in sections on LN obtained from study subjects.
Given that this is an exploratory endpoint, these assays will be performed in a subset of subjects (5 losartan treated, 2 placebo treated and 5 HIV uninfected controls).
|
30 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Timothy Schacker, M.D., University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- Fibrosis
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
Other Study ID Numbers
- 1111M06585
- 13-3613 (Other Identifier: Hennepin County Medical Center)
- U01AI105872 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Erasmus Medical CenterCompletedHIV/AIDS | Opportunistic Infections, HIV RelatedNetherlands
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
Clinical Trials on Losartan
-
Baker Heart and Diabetes InstituteWithdrawn
-
National Institute of Diabetes and Digestive and...Johns Hopkins UniversityTerminatedNAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
Chinese PLA General HospitalTianjin TongRenTang Group Co., Ltd.UnknownProteinuria | GlomerulonephritisChina
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Organon and CoTerminated
-
University of South FloridaNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
-
Vifor PharmaCompleted
-
EMSSuspended
-
Steadman Philippon Research InstituteRecruitingKnee Arthroplasty, TotalUnited States